133 related articles for article (PubMed ID: 38501689)
21. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.
Yadav J; Paragas E; Korzekwa K; Nagar S
Pharmacol Ther; 2020 Feb; 206():107449. PubMed ID: 31836452
[TBL] [Abstract][Full Text] [Related]
22. Risk Assessment Using Cytochrome P450 Time-Dependent Inhibition Assays at Single Time and Concentration in the Early Stage of Drug Discovery.
Kosaka M; Kosugi Y; Hirabayashi H
J Pharm Sci; 2017 Sep; 106(9):2839-2846. PubMed ID: 28483425
[TBL] [Abstract][Full Text] [Related]
23. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
24. Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
Cheng Y; Ma L; Chang SY; Humphreys WG; Li W
Drug Metab Dispos; 2016 Aug; 44(8):1372-80. PubMed ID: 27226352
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
26. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
Grime KH; Bird J; Ferguson D; Riley RJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
[TBL] [Abstract][Full Text] [Related]
27. Prediction of Cytochrome P450 Inhibition Using a Deep Learning Approach and Substructure Pattern Recognition.
Chen Z; Zhang L; Zhang P; Guo H; Zhang R; Li L; Li X
J Chem Inf Model; 2024 Apr; 64(7):2528-2538. PubMed ID: 37864562
[TBL] [Abstract][Full Text] [Related]
28. Drug Interactions Involving 17α-Ethinylestradiol: Considerations Beyond Cytochrome P450 3A Induction and Inhibition.
Rodrigues AD
Clin Pharmacol Ther; 2022 Jun; 111(6):1212-1221. PubMed ID: 34342002
[TBL] [Abstract][Full Text] [Related]
29. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
Chen Y; Liu L; Monshouwer M; Fretland AJ
Drug Metab Dispos; 2011 Nov; 39(11):2085-92. PubMed ID: 21835977
[TBL] [Abstract][Full Text] [Related]
30. NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition.
Kosaka M; Zhang D; Wong S; Yan Z
Drug Metab Dispos; 2020 Aug; 48(8):655-661. PubMed ID: 32482757
[TBL] [Abstract][Full Text] [Related]
31. Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data.
Yamashita F; Sasa Y; Yoshida S; Hisaka A; Asai Y; Kitano H; Hashida M; Suzuki H
PLoS One; 2013; 8(9):e70330. PubMed ID: 24086247
[TBL] [Abstract][Full Text] [Related]
32. Prediction of Human Cytochrome P450 Inhibition Using a Multitask Deep Autoencoder Neural Network.
Li X; Xu Y; Lai L; Pei J
Mol Pharm; 2018 Oct; 15(10):4336-4345. PubMed ID: 29775322
[TBL] [Abstract][Full Text] [Related]
33. Prediction of the Contribution Ratio of a Target Metabolic Enzyme to Clearance from Chemical Structure Information.
Watanabe R; Kawata T; Ueda S; Shinbo T; Higashimori M; Natsume-Kitatani Y; Mizuguchi K
Mol Pharm; 2023 Jan; 20(1):419-426. PubMed ID: 36538346
[TBL] [Abstract][Full Text] [Related]
34. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
[TBL] [Abstract][Full Text] [Related]
35. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Ou Y; Xu Y; Gore L; Harvey RD; Mita A; Papadopoulos KP; Wang Z; Cutler RE; Pinchasik DE; Tsimberidou AM
Br J Clin Pharmacol; 2019 Mar; 85(3):530-539. PubMed ID: 30428505
[TBL] [Abstract][Full Text] [Related]
36. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
37. Examination of the Impact of CYP3A4/5 on Drug-Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach.
He Q; Bu F; Wang Q; Li M; Lin J; Tang Z; Mak WY; Zhuang X; Zhu X; Lin HS; Xiang X
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562875
[TBL] [Abstract][Full Text] [Related]
38. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.
Youdim KA; Lyons R; Payne L; Jones BC; Saunders K
J Pharm Biomed Anal; 2008 Sep; 48(1):92-9. PubMed ID: 18584988
[TBL] [Abstract][Full Text] [Related]
39. Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition.
Zientek M; Stoner C; Ayscue R; Klug-McLeod J; Jiang Y; West M; Collins C; Ekins S
Chem Res Toxicol; 2010 Mar; 23(3):664-76. PubMed ID: 20151638
[TBL] [Abstract][Full Text] [Related]
40. Statistical methods for analysis of time-dependent inhibition of cytochrome p450 enzymes.
Yates P; Eng H; Di L; Obach RS
Drug Metab Dispos; 2012 Dec; 40(12):2289-96. PubMed ID: 22942318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
